Carbapenem-resistant Enterobacteriaceae Infection Epidemiology

Carbapenem-resistant Enterobacteriaceae (CRE) Infection Insights and Trends

• According to DelveInsight’s analysis, the total incident cases of CRE were ~23,000 in the 7MM (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• CRE infection is more prevalent in Asian countries such as Japan due to high healthcare-associated transmission rates, extensive use of broad-spectrum antibiotics, an aging population with frequent hospitalization, and the increasing spread of carbapenemase-producing Gram-negative pathogens within healthcare settings.
• Population growth, rising healthcare-associated infections, extensive use of broad-spectrum antibiotics, increasing antimicrobial resistance, and the growing incidence of immunocompromised and critically ill patients are expected to sustain the global burden of CRE infections over the next decade. Strengthening antimicrobial stewardship programs, improving infection prevention and surveillance, enabling rapid diagnostics, and expanding access to effective novel antibiotics will remain key determinants of future trends.

Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Epidemiology Forecast

• 2025 Incident Cases of CRE infection: ~23,000  
• 2036 Projected Incident Cases of CRE infection: XXXX
• CRE infection Growth Rate (2026–2036): ~XX% CAGR

DelveInsight's ‘Carbapenem-resistant Enterobacteriaceae (CRE) Infection Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the CRE Infection, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan.

Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Understanding and Diagnosis Algorithm

CRE Overview

Carbapenem-Resistant Enterobacteriaceae Infection is a serious and often life-threatening bacterial infection caused by Enterobacteriaceae resistant to carbapenem antibiotics, primarily affecting hospitalized and immunocompromised patients. These infections commonly involve the bloodstream, lungs, urinary tract, and wounds, and are driven by factors such as antibiotic overuse, prolonged healthcare exposure, invasive medical procedures, and transmission within healthcare settings.

CRE Diagnosis

Carbapenem-Resistant Enterobacteriaceae Infection is diagnosed through clinical assessment, microbiological culture, and antimicrobial susceptibility testing to identify carbapenem-resistant organisms. Common specimens include blood, urine, respiratory secretions, and wound samples. Molecular diagnostic methods, such as PCR, may be used to detect carbapenemase genes, including KPC, NDM, OXA-48, VIM, and IMP. Additional laboratory and imaging studies are often performed to determine the source, extent, and severity of infection.

Further details are provided in the report.

Carbapenem-Resistant Enterobacteriaceae Infection (CRE) Epidemiology

Key Findings from CRE Epidemiological Analysis and Forecast 

• According to DelveInsight’s estimates, the total incident cases of CRE infection in the 7MM were approximately 23,000 in 2025.
• The US, in 2025, accounted for around 14,000 incident cases of CRE infection, which will increase by the year 2036.
• Among the EU4, Italy accounted for the highest number of incident cases of CRE infection, followed by France, whereas Germany accounted for the lowest number of cases in 2025.
• In 2025, there were approximately 350 cases of CRE infections in Japan, which will increase by 2036.
• Males represent approximately 60% of all reported CRE Infection cases. 

Scope of the Report

• The report covers a segment of an executive summary, a descriptive overview of CRE Infection, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Carbapenem-Resistant Enterobacteriaceae (CRE) Infection Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (epi‑based) Bottom‑up Forecasting
• 11-year Forecast 
• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of CRE Infection? What will be the growth opportunities across the 7MM concerning the patient population with CRE?
• What is the historical and forecasted CRE Infection patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives on the diagnostic challenges to overcome barriers in the future.
• Detailed insights into various factors hampering disease diagnosis and other existing diagnostic challenges.